Aumolertinib clinical trials
Also written Almonertinib and HS-10296.
How each study uses aumolertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aumolertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 12 Feb 2026 · Aumseqa · EMEA/H/C/006069 (EMA; now revoked)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2021 (15)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 8 |
| 2021 | 15 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 35
Jiangsu Hansoh Pharmaceutical Co., Ltd. (8) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · Sun Yat-sen University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Shanghai Pulmonary Hospital, Shanghai, China (2) · EQRx International, Inc. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Qianfoshan Hospital (2)
Often tested with
Tested in the same studies.
Ruzaltatug rezetecan (2) · Pemetrexed (1) · Cisplatin (1) · Adebrelimab (1) · C-Met Inhibitor HS-10241 (1) · Anlotinib (1) · SHR-1701 (1) · Microwave Ablation (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test aumolertinib, phase 3 first.
- Dec 2026MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)Phase 3 · Guangdong Association of Clinical Trials
- Jan 2027Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerPhase 2 · Peking Union Medical College Hospital
- Mar 2027A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsPhase 1/2 · Sun Yat-sen University
- May 2027A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCPhase 2 · Sichuan University
- Jul 2027Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerPhase 1/2 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses aumolertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07863167Written as almonertinib combined with SHR-A2009
- MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNot applicablePeking University People's HospitalNCT07873086Written as Aumolertinib
- A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07130916Written as Aumolertinib
- A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingPhase 2Sichuan UniversityNCT06951464Written as Almonertinib
- A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingPhase 1/2Sun Yat-sen UniversityNCT06947811Written as Almonertinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Almonertinib 110 MG
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06752408Written as Aumolertinib
- Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06463171Written as Almonertinib
- Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05946460Written as Aumolertinib
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06110663Written as HS-10241+ Almonertinib
- Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingPhase 3Qianfoshan HospitalNCT06043973Written as almonertinib
- Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNot yet recruitingPhase 2/3Laibin People's HospitalNCT05994339Written as Almonertinib
- Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade PatternsRecruitingPhase 2Baohui HanNCT04922138Written as Aumolertinib
- Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05778149Written as Aumolertinib,Anlotinib
- Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyRecruitingPhase 2West China HospitalNCT05662813Written as Almonertinib
- Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerNot yet recruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05503888Written as Almonertinib combined with SHR-1701
- A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04951635Written as Almonertinib
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationPhase 3Chinese Academy of Medical SciencesNCT04762459Written as Almonertinib
- Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerNot yet recruitingPhase 2Qianfoshan HospitalNCT04755738Written as Almonertinib plus microwave ablation
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT04455594Written as Almonertinib
See all 50 studies that test aumolertinib →
Given beside what is tested · 6 — aumolertinib is usual care or a partner of the new treatment
- First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingPhase 2Yongsheng WangNCT07699952Written as Almonertinib
- PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07645222Written as HS-20122+Aumolertinib
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Hansoh BioMedical R&D CompanyNCT06417008Written as Aumolertinib
- Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung CancerRecruitingPhase 3Shanghai Cancer Hospital, ChinaNCT05800223Written as Almonertinib
- Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesRecruitingPhase 3Sun Yat-sen UniversityNCT05768490Written as Almonertinib
- Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerStatus unknownPhase 2Fudan UniversityNCT04592666Written as Almonertinib
Codes
What other systems call aumolertinib · ClinicalTrials.gg INT001649
- MeSH (NLM) C000718108aumolertinibOne source NLM
- UNII (FDA) T4RS462G19AUMOLERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105317437aumolertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C133691AumolertinibOne source FDA
- DrugBank DB16640One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718108 | aumolertinib | One source NLM |
| UNII (FDA) | T4RS462G19 | AUMOLERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105317437 | aumolertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C133691 | Aumolertinib | One source FDA |
| DrugBank | DB16640 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.